The market was waiting for a binary Phase 3 verdict, not another development update. Aspire data were expected in the September–October 2026 window, and management had framed statistical success as meeting either the Bayley-4 cognition threshold or the MDRI threshold. There was no reliable published numerical consensus to compare against, so the clean benchmark is the study's predefined efficacy bar and the prior Phase 1/2 signal.
The readout is decisively below that bar: neither efficacy measure separated from control. The filing says Aspire “did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index.” 〔0〕 It further states that there were no treatment-control differences supporting efficacy in the Bayley cognition scores, MDRI net response, or the five individual MDRI components. 〔1〕
The result materially weakens the apazunersen investment case and creates an immediate capital-allocation overhang. Ultragenyx is not committing to continue the program; it will evaluate the asset's disposition, while also assessing “significant expense reductions.” 〔2〕 〔3〕 The safety result was not the problem—the observed profile was consistent with Phase 1/2—so the negative signal is concentrated in efficacy and the possibility that prior uncontrolled evidence does not translate into a controlled benefit. 〔4〕
Read the original 8-K on SEC EDGAR ↗